硼替佐米治療多發性骨髓瘤的應用進展_《華西醫學》

作者：

何東 ^1,2 ,  牛挺 ¹

關鍵詞：

多發性骨髓瘤硼替佐米治療

DOI：

CNKI: 51-1356/R.20120214.1339.009

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

多發性骨髓瘤（MM）作為中老年常見的血液腫瘤之一，預后相對較差，常規化學療法（化療）療效欠理想。硼替佐米作為一種新藥，屬于蛋白酶體抑制劑，通過全新的機制達到抗骨髓瘤的作用。國內外臨床研究表明硼替佐米單藥以及同常規化療藥物組成的聯合化療方案對初始治療，以及復發難治的MM患者均有良好療效。因此以硼替佐米為主的聯合化療方案已被美國國家綜合癌癥協作網推薦作為MM患者治療的重要選擇之一。現將硼替佐米在MM治療上的進展作一綜述。

引用本文： 何東,牛挺. 硼替佐米治療多發性骨髓瘤的應用進展. 華西醫學, 2012, 27(2): 197-202. doi: CNKI: 51-1356/R.20120214.1339.009 復制

1.	葉任高, 陸再英. 內科學[M]. 6版. 北京: 人民衛生出版社, 2004: 631.
2.	高玉環, 劉海生. 血液系統惡性腫瘤現代非手術治療[M]. 北京: 科技文獻出版社, 2008: 157-158.
3.	張曉輝, 黃曉軍. 造血干細胞移植治療多發性骨髓瘤的研究進展 [J]. 國際輸血及血液學雜志, 2007, 30(4): 328-331.
4.	Kenneth CA, Melissa A, William B, et al. NCCN clinical practice guidelines in oncology multiple myeloma version I[S]. 2011: 17.
5.	Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase Ⅱ clinical trial[J]. Leukemia, 2009, 23(7): 1337-1341.
6.	Hideshima T, Miltiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341[J]. Blood, 2003, 101(4): 1530-1534.
7.	Jullig M, Zhang WV, Ferreira A, et al. MG132 induced apoptosis is associated with P53-independent induction of pro-apoptotic NOXA and transcriptional activity of beta-catenin [J]. Apoptosis, 2006, 11(4): 627-641.
8.	Roccaro AM, Hideshima T, Raje N, et al. Bortezomib mediates antiangi ogenesis in multiple myeloma via direct and indirect effects on endothelia1 cells[J]. Cancer Ras, 2006, 66(1): 184-191.
9.	National Comprehensive Cancer Net work (NCCN). NCCN clinical practice guidelines in oncology TM multiple myeloma (V.3.2008).http//www. nccn.org/peofessionals/physician_gle/PDF/myeloma.pdf.
10.	National Comprehensive Cancer Net work(NCCN). NCCN clinical practice guidelines in oncology multiple myeloma (V.1.2011). http://www.nccn.org/peofessionals/physician_gle/PDF/myeloma.pdf.
11.	Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma[J]. Br J Haematol, 2005, 129(6): 776-783.
12.	Harousseau JL, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase Ⅱ study[J]. Haematologica, 2006, 91(11): 1498-1505.
13.	Harousseau JL , Attal M , Avet-Loiseau H , et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase Ⅲ trial[J]. J Clin Oncol, 2010, 28(30): 4621-4629.
14.	Corso A , Barbarano L , Mangiacavalli S , et al. Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma[J]. Leuk Lymphoma, 2010, 51(2): 236-242.
15.	Cavo M, Tacchetti P, Patriarca F, et al. Superior complete response rate and progression-free survival after autologous transplantation with up-front velcade-thalidomide-dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma[J]. Blood, 2008, 112(11): 65.
16.	Sonneveld P, van der Holt B, Schmidt-Wolf IGH, et al. First analysis of HOVON-65/GMMG-HD4 randomized phase Ⅲ trial comparing bortezomib, adriamycine, dexamethasone (pad) vs vad as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM)[J]. ASH Annual Meeting Abstracts, 2008, 112(11): 653.
17.	Rajkumar SV, Hayman SR,Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma[J]. Blood, 2005, 106(13): 4050-4053.
18.	Richardson P, Lonial S, Jakubowiak A, et al. Lenalidomide, bortezomib,and dexamethasone in patients with newly diagnosed multiple myeloma:encouraging effcacy in high risk Groups with updated results of a phaseⅠ/Ⅱ study[J]. ASH Annual Meeting Abstracts, 2008,112(11): 92.
19.	Corso A , Barbarano L , Mangiacavalli S , et al. Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma [J]. Leuk Lymphoma, 2010, 51(2): 236-242.
20.	何東, 劉志剛, 喻琴梅, 等. 硼替佐米提高多發性骨髓瘤干細胞采集的臨床研究[J]. 華西醫學, 2011, 26(4): 521-523.
21.	Chari A, Mazumder M, Jagannath S. Proteasome inhibition and its therapeutic potential in multiple myeloma[J]. Biologics: Targets & Therapy, 2010, 4(10): 273-287.
22.	Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase Ⅲ VISTA trial[J]. J Clin Oncol, 2010, 28(13): 2259-2266.
23.	Palumbo A, Bringhen S, Rossi D, et al. A prospective, randomized, phase Ⅲ study of bortezomib, melphalan, prednisone and thalidomide (VMPT) versus bortezomib, melphalan and prednisone (VMP) in elderly newly diagnosed myeloma patients[J]. ASH Annual Meeting Abstracts, 2008, 112(11): 652.
24.	Rotta M, Storer BE, Sahebi F, et al. Long-term outcomeof patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting[J]. Blood, 2009, 113(14): 3383-3391.
25.	Mandelli F, Avvisati G, Amadori S, et al. Maintenance treatment with recombinant interferon alfa-2b inpatients with multiple myeloma responding to conventional induction chemotherapy[J]. N Engl J Med,1990, 322(10): 1430-1434.
26.	Berenson JR, Crowley JJ, Grogan TM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients[J]. Blood, 2002, 99(9): 3163-3168.
27.	Spencer A, Prince HM, Roberts AW, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure[J]. J Clin Oncol, 2009, 27(11): 1788-1793.
28.	Attal M, Harousseau JL, Leyvraz S, et al. Maintenanc therapy with thalidomide improves survival in patients with multiple myeloma[J]. Blood, 2006, 108(10): 3289-3294.
29.	Dispenzieri A , Jacobus S , Vesole DH , et al. Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial[J]. Leukemia , 2010, 24(8): 1406-1411.
30.	Benevolo G, Larocca A, Gentile M, et al. The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens[J]. Cancer, 2010, 117(9):1884-1890.
31.	Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial[J]. J Clin Oncol, 2010, 28(34): 5101-5109.
32.	Uy GL, Goyal SD, Fisher NM, et al. Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase Ⅱ study[J]. Bone Marrow Transplant, 2009, 43(10): 793-800.
33.	Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma[J]. N Engl J Med, 2003, 348(26): 2609-2617.
34.	Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or highdose dexamethasone for relapsed multiple myeloma[J]. N Engl J Med, 2005, 352(24): 2487-2498.
35.	Giuliani N, Morandi F, Tagliaferri S, et al. The proteasome inhibitor bort e zomib affects osteoblast differentiation in vitro and in vivo i n multiple myeloma patients[J]. Blood, 2007, 110(1): 334-338.
36.	Terpos E, Sezer O, Croucher P, et al. Myeloma bone disease and proteasome inhibition therapies[J]. Blood, 2007, 110(4): 1098-1104.
37.	Pineda-Roman M , Zangari M , van Rhee F , et al. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia[J]. 2008, 22(7): 1419-1427.
38.	Palumbo A , Gay F , Bringhen S , Falcone A , et al. Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma[J]. Ann Oncol, 2008, 19(6): 1160-1165.
39.	Palumbo A , Ambrosini MT , Benevolo G , et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma[J]. Blood, 2007, 109(7): 2767-2772.
40.	Richardson P, Jagannath S, Jakubowiak A, et al. Lenalidomide, bortezomib, and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (MM): encouraging response rates and tolerability with correlation of outcome and adverse cytogenetics in a phaseⅡ study[J]. ASH Annual Meeting Abstracts, 2008, 112(11): 1742.
41.	Roussou M, Kastritis E, Migkou M, et al. Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens[J]. Leuk Lymphoma, 2008, 49(5): 890-895. [42] Ludwig H, Drach J, Graf H, et al. Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma[J]. Haematologica, 2007, 92(10): 1411-1414.
42.	Chanan-Khan AA, Kaufman JL, Mehta J, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failu re: a multicenter retrospective study[J]. Blood, 2007, 109(6): 2604-2606. [44] Ludwig H , Adam Z , Hajek R , et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phaseⅡ study[J]. J Clin Oncol , 2010, 28(30): 4635-4641.
43.	Lonial S, Waller EK, Richardson PG, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma[J]. Blood, 2005, 106(12): 3777-3784.
44.	Johnston JA, Ward CL, Kopito RR. Aggresomes: a cellular response to misfolded proteins[J]. J Cell Biol, 1998, 143(7): 1883-1898.
45.	Cavaletti G, Gilardini A, Canta A, et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat[J]. Exp Neurol, 2007, 204(1): 317-325.
46.	Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility f peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib[J]. J Clin Oncol, 2006, 24(19): 3113-3120.
47.	Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase Ⅲ APEX trial in relapsed multiple myeloma: impact of adose-modifcationguideline[J]. Br J Haematol, 2009, 144(6): 895-903.
48.	Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature[J]. Blood, 2008, 112(5): 1593-1599.
49.	何群, 趙謝蘭, 賀艷娟, 等. 硼替佐米聯合地塞米松治療多發性骨髓瘤的臨床分析[J]. 中南大學學報(醫學版), 2010, 35(8): 864-867.
50.	李娟, 趙瑩, 羅紹凱, 等. 硼替佐米聯合地塞米松治療24例多發性骨髓瘤的療效分析[J]. 癌癥, 2008, 27(4): 429-434.
51.	劉志剛, 牛挺, 向兵, 等. 硼替佐米為主化療方案治療多發性骨髓瘤的臨床研究[J]. 四川大學學報(醫學版), 2009, 40(2): 358-360.

1. 葉任高, 陸再英. 內科學[M]. 6版. 北京: 人民衛生出版社, 2004: 631.
2. 高玉環, 劉海生. 血液系統惡性腫瘤現代非手術治療[M]. 北京: 科技文獻出版社, 2008: 157-158.
3. 張曉輝, 黃曉軍. 造血干細胞移植治療多發性骨髓瘤的研究進展 [J]. 國際輸血及血液學雜志, 2007, 30(4): 328-331.
4. Kenneth CA, Melissa A, William B, et al. NCCN clinical practice guidelines in oncology multiple myeloma version I[S]. 2011: 17.
5. Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase Ⅱ clinical trial[J]. Leukemia, 2009, 23(7): 1337-1341.
6. Hideshima T, Miltiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341[J]. Blood, 2003, 101(4): 1530-1534.
7. Jullig M, Zhang WV, Ferreira A, et al. MG132 induced apoptosis is associated with P53-independent induction of pro-apoptotic NOXA and transcriptional activity of beta-catenin [J]. Apoptosis, 2006, 11(4): 627-641.
8. Roccaro AM, Hideshima T, Raje N, et al. Bortezomib mediates antiangi ogenesis in multiple myeloma via direct and indirect effects on endothelia1 cells[J]. Cancer Ras, 2006, 66(1): 184-191.
9. National Comprehensive Cancer Net work (NCCN). NCCN clinical practice guidelines in oncology TM multiple myeloma (V.3.2008).http//www. nccn.org/peofessionals/physician_gle/PDF/myeloma.pdf.
10. National Comprehensive Cancer Net work(NCCN). NCCN clinical practice guidelines in oncology multiple myeloma (V.1.2011). http://www.nccn.org/peofessionals/physician_gle/PDF/myeloma.pdf.
11. Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma[J]. Br J Haematol, 2005, 129(6): 776-783.
12. Harousseau JL, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase Ⅱ study[J]. Haematologica, 2006, 91(11): 1498-1505.
13. Harousseau JL , Attal M , Avet-Loiseau H , et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase Ⅲ trial[J]. J Clin Oncol, 2010, 28(30): 4621-4629.
14. Corso A , Barbarano L , Mangiacavalli S , et al. Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma[J]. Leuk Lymphoma, 2010, 51(2): 236-242.
15. Cavo M, Tacchetti P, Patriarca F, et al. Superior complete response rate and progression-free survival after autologous transplantation with up-front velcade-thalidomide-dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma[J]. Blood, 2008, 112(11): 65.
16. Sonneveld P, van der Holt B, Schmidt-Wolf IGH, et al. First analysis of HOVON-65/GMMG-HD4 randomized phase Ⅲ trial comparing bortezomib, adriamycine, dexamethasone (pad) vs vad as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM)[J]. ASH Annual Meeting Abstracts, 2008, 112(11): 653.
17. Rajkumar SV, Hayman SR,Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma[J]. Blood, 2005, 106(13): 4050-4053.
18. Richardson P, Lonial S, Jakubowiak A, et al. Lenalidomide, bortezomib,and dexamethasone in patients with newly diagnosed multiple myeloma:encouraging effcacy in high risk Groups with updated results of a phaseⅠ/Ⅱ study[J]. ASH Annual Meeting Abstracts, 2008,112(11): 92.
19. Corso A , Barbarano L , Mangiacavalli S , et al. Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma [J]. Leuk Lymphoma, 2010, 51(2): 236-242.
20. 何東, 劉志剛, 喻琴梅, 等. 硼替佐米提高多發性骨髓瘤干細胞采集的臨床研究[J]. 華西醫學, 2011, 26(4): 521-523.
21. Chari A, Mazumder M, Jagannath S. Proteasome inhibition and its therapeutic potential in multiple myeloma[J]. Biologics: Targets & Therapy, 2010, 4(10): 273-287.
22. Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase Ⅲ VISTA trial[J]. J Clin Oncol, 2010, 28(13): 2259-2266.
23. Palumbo A, Bringhen S, Rossi D, et al. A prospective, randomized, phase Ⅲ study of bortezomib, melphalan, prednisone and thalidomide (VMPT) versus bortezomib, melphalan and prednisone (VMP) in elderly newly diagnosed myeloma patients[J]. ASH Annual Meeting Abstracts, 2008, 112(11): 652.
24. Rotta M, Storer BE, Sahebi F, et al. Long-term outcomeof patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting[J]. Blood, 2009, 113(14): 3383-3391.
25. Mandelli F, Avvisati G, Amadori S, et al. Maintenance treatment with recombinant interferon alfa-2b inpatients with multiple myeloma responding to conventional induction chemotherapy[J]. N Engl J Med,1990, 322(10): 1430-1434.
26. Berenson JR, Crowley JJ, Grogan TM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients[J]. Blood, 2002, 99(9): 3163-3168.
27. Spencer A, Prince HM, Roberts AW, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure[J]. J Clin Oncol, 2009, 27(11): 1788-1793.
28. Attal M, Harousseau JL, Leyvraz S, et al. Maintenanc therapy with thalidomide improves survival in patients with multiple myeloma[J]. Blood, 2006, 108(10): 3289-3294.
29. Dispenzieri A , Jacobus S , Vesole DH , et al. Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial[J]. Leukemia , 2010, 24(8): 1406-1411.
30. Benevolo G, Larocca A, Gentile M, et al. The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens[J]. Cancer, 2010, 117(9):1884-1890.
31. Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial[J]. J Clin Oncol, 2010, 28(34): 5101-5109.
32. Uy GL, Goyal SD, Fisher NM, et al. Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase Ⅱ study[J]. Bone Marrow Transplant, 2009, 43(10): 793-800.
33. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma[J]. N Engl J Med, 2003, 348(26): 2609-2617.
34. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or highdose dexamethasone for relapsed multiple myeloma[J]. N Engl J Med, 2005, 352(24): 2487-2498.
35. Giuliani N, Morandi F, Tagliaferri S, et al. The proteasome inhibitor bort e zomib affects osteoblast differentiation in vitro and in vivo i n multiple myeloma patients[J]. Blood, 2007, 110(1): 334-338.
36. Terpos E, Sezer O, Croucher P, et al. Myeloma bone disease and proteasome inhibition therapies[J]. Blood, 2007, 110(4): 1098-1104.
37. Pineda-Roman M , Zangari M , van Rhee F , et al. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia[J]. 2008, 22(7): 1419-1427.
38. Palumbo A , Gay F , Bringhen S , Falcone A , et al. Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma[J]. Ann Oncol, 2008, 19(6): 1160-1165.
39. Palumbo A , Ambrosini MT , Benevolo G , et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma[J]. Blood, 2007, 109(7): 2767-2772.
40. Richardson P, Jagannath S, Jakubowiak A, et al. Lenalidomide, bortezomib, and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (MM): encouraging response rates and tolerability with correlation of outcome and adverse cytogenetics in a phaseⅡ study[J]. ASH Annual Meeting Abstracts, 2008, 112(11): 1742.
41. Roussou M, Kastritis E, Migkou M, et al. Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens[J]. Leuk Lymphoma, 2008, 49(5): 890-895. [42] Ludwig H, Drach J, Graf H, et al. Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma[J]. Haematologica, 2007, 92(10): 1411-1414.
42. Chanan-Khan AA, Kaufman JL, Mehta J, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failu re: a multicenter retrospective study[J]. Blood, 2007, 109(6): 2604-2606. [44] Ludwig H , Adam Z , Hajek R , et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phaseⅡ study[J]. J Clin Oncol , 2010, 28(30): 4635-4641.
43. Lonial S, Waller EK, Richardson PG, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma[J]. Blood, 2005, 106(12): 3777-3784.
44. Johnston JA, Ward CL, Kopito RR. Aggresomes: a cellular response to misfolded proteins[J]. J Cell Biol, 1998, 143(7): 1883-1898.
45. Cavaletti G, Gilardini A, Canta A, et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat[J]. Exp Neurol, 2007, 204(1): 317-325.
46. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility f peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib[J]. J Clin Oncol, 2006, 24(19): 3113-3120.
47. Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase Ⅲ APEX trial in relapsed multiple myeloma: impact of adose-modifcationguideline[J]. Br J Haematol, 2009, 144(6): 895-903.
48. Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature[J]. Blood, 2008, 112(5): 1593-1599.
49. 何群, 趙謝蘭, 賀艷娟, 等. 硼替佐米聯合地塞米松治療多發性骨髓瘤的臨床分析[J]. 中南大學學報(醫學版), 2010, 35(8): 864-867.
50. 李娟, 趙瑩, 羅紹凱, 等. 硼替佐米聯合地塞米松治療24例多發性骨髓瘤的療效分析[J]. 癌癥, 2008, 27(4): 429-434.
51. 劉志剛, 牛挺, 向兵, 等. 硼替佐米為主化療方案治療多發性骨髓瘤的臨床研究[J]. 四川大學學報(醫學版), 2009, 40(2): 358-360.

上一篇
硼替佐米治療多發性骨髓瘤的臨床護理
下一篇
噬血細胞綜合征的臨床研究進展

《華西醫學》

硼替佐米治療多發性骨髓瘤的應用進展

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

《華西醫學》

硼替佐米治療多發性骨髓瘤的應用進展

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料